His primary areas of study are Cannabinoid receptor, Cannabinoid, Anandamide, Receptor and Pharmacology. His Cannabinoid receptor study improves the overall literature in Internal medicine. His biological study spans a wide range of topics, including Agonist, Cannabinoid receptor antagonist, Antagonist, Cannabinoid receptor type 2 and Stereochemistry.
His Stereochemistry study combines topics from a wide range of disciplines, such as CP 55,940 and Potency. His Anandamide course of study focuses on Endocannabinoid system and Biological activity, Opioid antagonist and Route of administration. As part of the same scientific family, Raj K. Razdan usually focuses on Pharmacology, concentrating on GPR18 and intersecting with Signal transduction.
Raj K. Razdan mainly investigates Stereochemistry, Cannabinoid, Pharmacology, Cannabinoid receptor and Organic chemistry. His Stereochemistry research incorporates themes from Biological activity, Structure–activity relationship, Potency and Chemical synthesis. He has researched Cannabinoid in several fields, including Agonist, Cannabinoid receptor antagonist, Antagonist, Cannabinoid receptor type 2 and Anandamide.
His study in Anandamide is interdisciplinary in nature, drawing from both Fatty acid amide hydrolase and Endocannabinoid system. His research in Pharmacology tackles topics such as Tetrahydrocannabinol which are related to areas like Metabolite. His study looks at the intersection of Cannabinoid receptor and topics like Endocrinology with Abnormal cannabidiol.
Cannabinoid, Cannabinoid receptor, Pharmacology, Anandamide and Cannabinoid receptor type 2 are his primary areas of study. His Cannabinoid study integrates concerns from other disciplines, such as Anesthesia, Cannabinoid receptor antagonist, Antagonist, Cannabinoid Receptor Agonists and Biological activity. The various areas that he examines in his Cannabinoid receptor study include Endocrinology and Tetrahydrocannabinol.
His research integrates issues of Agonist, Cannabidiol, Rimonabant, Appetite and Receptor antagonist in his study of Pharmacology. His Anandamide research includes themes of Fatty acid amide hydrolase, Stereochemistry and Endocannabinoid system. His Stereochemistry study incorporates themes from Alkene and Chemical synthesis.
Raj K. Razdan mostly deals with Cannabinoid, Cannabinoid receptor, Anandamide, Biochemistry and Pharmacology. His Cannabinoid study frequently draws connections to other fields, such as Agonist. His Cannabinoid receptor study necessitates a more in-depth grasp of Internal medicine.
His Anandamide research is multidisciplinary, relying on both Fatty acid amide hydrolase and Endocannabinoid system. In his study, which falls under the umbrella issue of Fatty acid amide hydrolase, Acylglycerol lipase is strongly linked to Stereochemistry. His Pharmacology research is multidisciplinary, incorporating perspectives in Abnormal cannabidiol, Cannabinoid receptor antagonist, Antagonist, Cannabinoid receptor type 2 and GPR18.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Zoltán Járai;Jens A. Wagner;Jens A. Wagner;Károly Varga;Kristy D. Lake.
Proceedings of the National Academy of Sciences of the United States of America (1999)
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.
D R Compton;K C Rice;B R De Costa;R K Razdan.
Journal of Pharmacology and Experimental Therapeutics (1993)
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.
Vincenzo Di Marzo;Chris S. Breivogel;Qing Tao;David T. Bridgen.
Journal of Neurochemistry (2008)
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
P B Smith;D R Compton;S P Welch;R K Razdan.
Journal of Pharmacology and Experimental Therapeutics (1994)
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
Adele Thomas;Gemma Baillie;A. M. Phillips;R. K. Razdan.
British Journal of Pharmacology (2007)
A biosynthetic pathway for anandamide
Jie Liu;Lei Wang;Judith Harvey-White;Douglas Osei-Hyiaman.
Proceedings of the National Academy of Sciences of the United States of America (2006)
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.
B. R. Martin;D. R. Compton;B. F. Thomas;W. R. Prescott.
Pharmacology, Biochemistry and Behavior (1991)
Multiple pathways involved in the biosynthesis of anandamide
Jie Liu;Lei Wang;Judith Harvey-White;Bill X. Huang.
Selective Ligands and Cellular Effectors of a G Protein-Coupled Endothelial Cannabinoid Receptor
László Offertáler;Fong-Ming Mo;Sándor Bátkai;Jie Liu.
Molecular Pharmacology (2003)
Discovery and characterization of endogenous cannabinoids.
B.R. Martin;R. Mechoulam;R.K. Razdan.
Life Sciences (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: